BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 32923389)

  • 1. Delivery of Personalized Care for Locally Advanced Rectal Cancer: Incorporating Pathological, Molecular Genetic, and Immunological Biomarkers Into the Multimodal Paradigm.
    Ryan ÉJ; Creavin B; Sheahan K
    Front Oncol; 2020; 10():1369. PubMed ID: 32923389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal Neoadjuvant Strategies for Locally Advanced Rectal Cancer by Risk Assessment and Tumor Location.
    Saraf A; Roberts HJ; Wo JY; Parikh AR
    J Natl Compr Canc Netw; 2022 Oct; 20(10):1177-1184. PubMed ID: 36240854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Evolving Neoadjuvant Treatment Paradigm for Patients with Locoregional mismatch Repair Proficient Rectal Cancer.
    Bhudia J; Glynne-Jones R
    Curr Treat Options Oncol; 2022 Apr; 23(4):453-473. PubMed ID: 35312962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and Assessment of a Clinical Calculator for Estimating the Likelihood of Recurrence and Survival Among Patients With Locally Advanced Rectal Cancer Treated With Chemotherapy, Radiotherapy, and Surgery.
    Weiser MR; Chou JF; Keshinro A; Chapman WC; Bauer PS; Mutch MG; Parikh PJ; Cercek A; Saltz LB; Gollub MJ; Romesser PB; Crane CH; Shia J; Markowitz AJ; Garcia-Aguilar J; Gönen M;
    JAMA Netw Open; 2021 Nov; 4(11):e2133457. PubMed ID: 34748003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.
    Smith JJ; Chow OS; Gollub MJ; Nash GM; Temple LK; Weiser MR; Guillem JG; Paty PB; Avila K; Garcia-Aguilar J;
    BMC Cancer; 2015 Oct; 15():767. PubMed ID: 26497495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma.
    Shamseddine A; Zeidan YH; Kreidieh M; Khalifeh I; Turfa R; Kattan J; Mukherji D; Temraz S; Alqasem K; Amarin R; Al Awabdeh T; Deeba S; Jamali F; Mohamad I; Elkhaldi M; Daoud F; Al Masri M; Dabous A; Hushki A; Jaber O; Khoury C; El Husseini Z; Charafeddine M; Al Darazi M; Geara F
    BMC Cancer; 2020 Sep; 20(1):831. PubMed ID: 32873251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant treatment for locally advanced rectal cancer: a systematic review.
    Uehara K; Nagino M
    Surg Today; 2016 Feb; 46(2):161-8. PubMed ID: 26170102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Total Neoadjuvant Therapy: A Shifting Paradigm in Locally Advanced Rectal Cancer Management.
    Franke AJ; Parekh H; Starr JS; Tan SA; Iqbal A; George TJ
    Clin Colorectal Cancer; 2018 Mar; 17(1):1-12. PubMed ID: 28803718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk ("ugly") locally advanced rectal cancer: study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT).
    van den Berg K; Schaap DP; Voogt ELK; Buffart TE; Verheul HMW; de Groot JWB; Verhoef C; Melenhorst J; Roodhart JML; de Wilt JHW; van Westreenen HL; Aalbers AGJ; van 't Veer M; Marijnen CAM; Vincent J; Simkens LHJ; Peters NAJB; Berbée M; Werter IM; Snaebjornsson P; Peulen HMU; van Lijnschoten IG; Roef MJ; Nieuwenhuijzen GAP; Bloemen JG; Willems JMWE; Creemers GJM; Nederend J; Rutten HJT; Burger JWA
    BMC Cancer; 2022 Sep; 22(1):957. PubMed ID: 36068495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective use of radiation for locally advanced rectal cancer: one size does not fit all.
    Roxburgh CS; Weiser MR
    Minerva Chir; 2018 Dec; 73(6):592-600. PubMed ID: 29806758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contemporary management of locally advanced rectal cancer: Resolving issues, controversies and shifting paradigms.
    Nacion AJD; Park YY; Kim NK
    Chin J Cancer Res; 2018 Feb; 30(1):131-146. PubMed ID: 29545727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolving role of neoadjuvant therapy in rectal cancer.
    Schrag D
    Curr Treat Options Oncol; 2013 Sep; 14(3):350-64. PubMed ID: 23828092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Short-course radiotherapy combined with CAPOX and PD-1 inhibitor for the total neoadjuvant therapy of locally advanced rectal cancer: the preliminary single-center findings of a prospective, multicentre, randomized phase II trial (TORCH)].
    Wang YQ; Shen LJ; Wan JF; Zhang H; Wang Y; Wu X; Wang JW; Wang RJ; Sun YQ; Tong T; Huang D; Wang L; Sheng WQ; Zhang X; Cai GX; Xu Y; Cai SJ; Zhang Z; Xia F
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):448-458. PubMed ID: 37217353
    [No Abstract]   [Full Text] [Related]  

  • 16. Implications of recent neoadjuvant clinical trials on the future practice of radiotherapy in locally advanced rectal cancer.
    Kang MK
    World J Gastroenterol; 2023 Feb; 29(6):1011-1025. PubMed ID: 36844136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT-PD1-LARC trial).
    Yang Z; Zhang X; Zhang J; Gao J; Bai Z; Deng W; Chen G; An Y; Liu Y; Wei Q; Han J; Li A; Liu G; Sun Y; Kong D; Yao H; Zhang Z
    BMC Cancer; 2022 Apr; 22(1):462. PubMed ID: 35477432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multidisciplinary management of locally advanced rectal cancer: neoadjuvant approaches.
    Murugappan S; Harris WP; Willett CG; Lin E
    J Natl Compr Canc Netw; 2013 May; 11(5):548-57. PubMed ID: 23667205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surgical treatment following neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
    Huang MY; Huang CW; Wang JY
    Kaohsiung J Med Sci; 2020 Mar; 36(3):152-159. PubMed ID: 31814296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Total neoadjuvant treatment to increase the clinical complete response rate for distal locally advanced rectal cancer (TESS): A study protocol of a prospective, open-label, multicenter, single-arm, phase 2 trial.
    Liu S; Wang X; Zhuang Y; Bai S; Wu X; Ye Y; Luo H; Yu H; Wang Q; Chang H; Zeng Z; Cai P; Pan Z; Gao Y; Chen G; Xiao W
    Cancer Med; 2023 Jun; 12(12):13352-13360. PubMed ID: 37156624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.